Zhejiang Gongdong Medical Technology Co., Ltd.

SHSE:605369 Rapport sur les actions

Capitalisation boursière : CN¥4.6b

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Zhejiang Gongdong Medical Technology Croissance future

Future contrôle des critères 5/6

Zhejiang Gongdong Medical Technology is forecast to grow earnings and revenue by 32.9% and 24% per annum respectively. EPS is expected to grow by 32.9% per annum. Return on equity is forecast to be 16.1% in 3 years.

Informations clés

32.9%

Taux de croissance des bénéfices

32.9%

Taux de croissance du BPA

Medical Equipment croissance des bénéfices22.5%
Taux de croissance des recettes24.0%
Rendement futur des capitaux propres16.1%
Couverture par les analystes

Low

Dernière mise à jour13 Jun 2024

Mises à jour récentes de la croissance future

Pas de mise à jour

Recent updates

Zhejiang Gongdong Medical Technology Co., Ltd.'s (SHSE:605369) P/E Still Appears To Be Reasonable

Jun 07
Zhejiang Gongdong Medical Technology Co., Ltd.'s (SHSE:605369) P/E Still Appears To Be Reasonable

Estimating The Intrinsic Value Of Zhejiang Gongdong Medical Technology Co., Ltd. (SHSE:605369)

Mar 28
Estimating The Intrinsic Value Of Zhejiang Gongdong Medical Technology Co., Ltd. (SHSE:605369)

Zhejiang Gongdong Medical Technology Co., Ltd. (SHSE:605369) Looks Just Right With A 27% Price Jump

Mar 06
Zhejiang Gongdong Medical Technology Co., Ltd. (SHSE:605369) Looks Just Right With A 27% Price Jump

Zhejiang Gongdong Medical Technology (SHSE:605369) Is Reinvesting At Lower Rates Of Return

Feb 27
Zhejiang Gongdong Medical Technology (SHSE:605369) Is Reinvesting At Lower Rates Of Return

Prévisions de croissance des bénéfices et des revenus

SHSE:605369 - Estimations futures des analystes et données financières antérieures (CNY Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/20262,0933824915442
12/31/20251,7343143644252
12/31/20241,4362531964152
3/31/20241,02112589188N/A
12/31/202397510964185N/A
9/30/20231,002106112189N/A
6/30/20231,128176136248N/A
3/31/20231,347260143268N/A
12/31/20221,469326111283N/A
9/30/20221,527367138382N/A
6/30/20221,4173443285N/A
3/31/20221,28032732350N/A
12/31/20211,19431197373N/A
9/30/20211,088319326269N/A
6/30/20211,068313208379N/A
3/31/2021989281177304N/A
12/31/2020830226134242N/A
9/30/2020744191-160220N/A
6/30/202063815558142N/A
3/31/202052911320113N/A
12/31/201955311420122N/A
12/31/20184838667102N/A
12/31/201743154N/A86N/A
12/31/201637161N/A86N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: 605369's forecast earnings growth (32.9% per year) is above the savings rate (2.9%).

Bénéfices vs marché: 605369's earnings (32.9% per year) are forecast to grow faster than the CN market (21.9% per year).

Croissance élevée des bénéfices: 605369's earnings are expected to grow significantly over the next 3 years.

Chiffre d'affaires vs marché: 605369's revenue (24% per year) is forecast to grow faster than the CN market (13.4% per year).

Croissance élevée des revenus: 605369's revenue (24% per year) is forecast to grow faster than 20% per year.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: 605369's Return on Equity is forecast to be low in 3 years time (16.1%).

Découvrir les entreprises en croissance

7D

1Y

7D

1Y

7D

1Y